Prestige Consumer Healthcare
PBH
#3966
Rank
C$4.06 B
Marketcap
C$82.56
Share price
-1.09%
Change (1 day)
-29.93%
Change (1 year)

P/E ratio for Prestige Consumer Healthcare (PBH)

P/E ratio as of December 2025 (TTM): 14.9

According to Prestige Consumer Healthcare's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 14.8547. At the end of 2024 the company had a P/E ratio of 18.2.

P/E ratio history for Prestige Consumer Healthcare from 2005 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202418.2-147.76%
2023-38.0-355.12%
202214.9-7.6%
202116.153.12%
202010.5-115.61%
2019-67.5-368.86%
201825.1316.07%
20176.03-84.13%
201638.053.65%
201524.7-3.05%
201425.55.54%
201324.2
201113.0

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
GlaxoSmithKline
GSK
13.5-9.26%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
15.0 0.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Rite Aid
RAD
-0.0219-100.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
19.3 30.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Taro Pharmaceutical
TARO
70.4 374.21%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Novartis
NVS
17.7 19.06%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Procter & Gamble
PG
19.7 32.47%๐Ÿ‡บ๐Ÿ‡ธ USA
CVS Health
CVS
191 1,187.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Clorox
CLX
15.7 6.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
15.2 2.01%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.